INO Therapeutics Overview
- Status
- Acquired/Merged
- Employees
- 463
- Latest Deal Type
- IPO
- (Cancelled)
- Financing Rounds
- 2
INO Therapeutics General Information
Description
Manufacturer of late stage drugs for the treatment of heart and lung functions. The company's primary offering INOmax is used to carry oxygenated blood to the body tissues, and for the treatment of persistant pulmonary hypertension in the newborn.
Contact Information
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Office
- Six State Route 173
- Clinton, NJ 08809
- United States
+1 (908) 000-0000
INO Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore INO Therapeutics‘s full profile, request access.
Request a free trialINO Therapeutics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Daniel Tassé | Chief Executive Officer | ||
| David Shaw | President |
INO Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialINO Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore INO Therapeutics‘s full profile, request access.
Request a free trial